Apple Turns 50: From Garage Startup to AI Crossroads 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
CAMBRIDGE, Mass., Aug. 30, 2017 -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that Richard Murray, Ph.D., chief executive officer of Jounce, will present at two upcoming investor conferences:
- Baird 2017 Global Healthcare Conference at 12:15 p.m. ET on Wednesday, September 6, 2017 in New York, NY
- 2017 Wells Fargo Healthcare Conference at 8:15 a.m. ET on Thursday, September 7, 2017 in Boston, MA
A live webcast of each presentation will be available by visiting “Events and Presentations” in the Investors and Media section of Jounce’s website at www.jouncetx.com. A replay of the webcasts will be archived for 30 days following each presentation.
About Jounce Therapeutics
Jounce Therapeutics, Inc. is a clinical stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long‑lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient. Jounce’s lead product candidate, JTX-2011, is a monoclonal antibody that binds to and activates ICOS and is currently in a Phase 2 trial. For more information, please visit www.jouncetx.com.
Media Contact: Katie Engleman Pure Communications, Inc. (910) 509-3977 [email protected] Investor Contact: Beth DelGiacco Stern Investor Relations, Inc. (212) 362-1200 [email protected]
